The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...

US President Donald Trump announced plans to impose tariffs on imported computer chips pharmaceuticals and steel aiming to ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Unveiling the Future of Chronic Insomnia treatment – DelveInsight's latest report explores epidemiological insights and market opportunities spanning the 7MM. LAS VEGAS , NV, UNITED STATES, January 31 ...

Shares of BioArctic AB tumbled by 7% on Friday following news that the European Commission (EC) has requested further review of the company's Alzheimer's drug, lecanemab, by the Committee for ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...